K
Kinnari Patel
Researcher at Churchill Hospital
Publications - 15
Citations - 2249
Kinnari Patel is an academic researcher from Churchill Hospital. The author has contributed to research in topics: Cancer & Gemcitabine. The author has an hindex of 9, co-authored 12 publications receiving 1420 citations. Previous affiliations of Kinnari Patel include University of Oxford.
Papers
More filters
Journal ArticleDOI
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos,John P. Neoptolemos,Daniel H. Palmer,Daniel H. Palmer,Paula Ghaneh,Eftychia E. Psarelli,Juan W. Valle,Christopher Halloran,Christopher Halloran,Olusola Olusesan Faluyi,Derek A. O'Reilly,David Cunningham,Jonathan Wadsley,Suzanne Darby,Tim Meyer,Roopinder Gillmore,Alan Anthoney,Pehr Lind,Bengt Glimelius,Stephen Falk,Jakob R. Izbicki,Gary Middleton,Sebastian Cummins,Paul Ross,Harpreet Wasan,Alec McDonald,Tom Crosby,Yuk Ting Ma,Kinnari Patel,David Sherriff,Rubin Soomal,David Borg,Sharmila Sothi,Pascal Hammel,Thilo Hackert,Richard J. Jackson,Markus W. Büchler +36 more
TL;DR: The adjuvant combination of gem citabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma.
Journal ArticleDOI
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
Angela Lamarca,Daniel H. Palmer,Harpreet Wasan,Paul Ross,Yuk Ting Ma,Arvind Arora,Stephen Falk,Roopinder Gillmore,Jonathan Wadsley,Kinnari Patel,Alan Anthoney,Anthony Maraveyas,Timothy Iveson,Justin S. Waters,Claire Hobbs,Safia Barber,W David J Ryder,John Ramage,Linda Davies,John Bridgewater,Juan W. Valle +20 more
TL;DR: The ABC-06 clinical trial was a phase 3, open-label, randomised trial done in 20 sites with expertise in managing biliary tract cancer across the UK.
Journal ArticleDOI
ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
Angela Lamarca,Daniel H. Palmer,Harpreet Wasan,Paul Ross,Yuk Ting Ma,Arvind Arora,Stephen Falk,Roopinder Gillmore,Jonathan Wadsley,Kinnari Patel,Alan Anthoney,Anthony Maraveyas,Justin S. Waters,Claire Hobbs,Safia Barber,David Ryder,John Ramage,Linda Davies,John Bridgewater,Juan W. Valle +19 more
TL;DR: Level A evidence supports use of CisGem as first-line chemotherapy for ABC and no robust evidence is available for second- line chemotherapy, but level B evidence is not available.
Journal ArticleDOI
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
Robert P. Jones,Eftychia-Eirini Psarelli,Richard J. Jackson,Paula Ghaneh,Paula Ghaneh,Christopher Halloran,Christopher Halloran,Daniel H. Palmer,Daniel H. Palmer,Fiona Campbell,Juan W. Valle,Olusola Olusesan Faluyi,Derek A. O'Reilly,David Cunningham,Jonathan Wadsley,Suzanne Darby,Tim Meyer,Roopinder Gillmore,Alan Anthoney,Pehr Lind,Bengt Glimelius,Stephen Falk,Jakob R. Izbicki,Gary Middleton,Sebastian Cummins,Paul Ross,Harpreet Wasan,Alec McDonald,Tom Crosby,Yuk Ting,Kinnari Patel,David Sherriff,Rubin Soomal,David Borg,Sharmila Sothi,Pascal Hammel,Markus M. Lerch,Julia Mayerle,Julia Mayerle,Christine Tjaden,Oliver Strobel,Thilo Hackert,Markus W. Büchler,John P. Neoptolemos +43 more
TL;DR: There were no significant differences between the time to recurrence and subsequent and overall survival between local and distant recurrence in patients who had resection and adjuvant chemotherapy for pancreatic cancer.
Journal ArticleDOI
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.
Julien Edeline,Jean-Frédéric Blanc,Philip J. Johnson,Philip J. Johnson,Boris Campillo-Gimenez,Paul Ross,Yuk Ting Ma,Yuk Ting Ma,Judy King,Richard A Hubner,K Sumpter,Suzanne Darby,Jeff Evans,Chinenye Iwuji,Daniel Swinson,Peter Collins,Kinnari Patel,Iqtedar Muazzam,Daniel H. Palmer,Daniel H. Palmer,Tim Meyer +20 more
TL;DR: The Albumin‐Bilirubin (ALBI) grade was proposed as an objective means to evaluate liver function in patients with Hepatocellular Carcinoma (HCC) but comparison with the subclassification by points (5–15) within the CP classification is not provided.